IRADIMED CORP (NASDAQ:IRMD) reported financial results for the fourth quarter and full year of 2025, delivering performance that exceeded analyst expectations on key metrics. The medical device maker, specializing in MRI-compatible infusion pumps and patient monitoring systems, also announced an increase to its quarterly dividend, signaling confidence in its financial stability and future cash generation.
Earnings and Revenue Performance Versus Estimates
The company’s fourth-quarter results surpassed the consensus estimates provided by analysts, contributing to a positive market reaction in pre-market trading.
- Q4 2025 Revenue: The company reported record revenue of $22.7 million, a 17% increase year-over-year. This comfortably exceeded the analyst estimate of $22.03 million.
- Q4 2025 Non-GAAP EPS: Earnings per share on a non-GAAP basis came in at $0.54, a 23% increase from the prior year. This result beat the analyst estimate of $0.49 per share.
For the full year 2025, IRadimed reported revenue of $83.8 million, a 14% increase, and non-GAAP diluted EPS of $1.93, a 16% increase. The company highlighted its eighteenth consecutive quarter of record revenue.
Market Reaction and Forward Guidance
The earnings beat was met with a positive response from investors. In pre-market trading following the announcement, the stock was indicated up approximately 6.3%. This move contrasts with the stock’s performance over the prior month, which had seen a slight decline.
Management provided financial guidance for the upcoming year, which appears to be in line with or slightly above current analyst expectations.
- Full-Year 2026 Outlook: IRadimed expects revenue in the range of $91.0 million to $96.0 million. The midpoint of this range ($93.5 million) is above the analyst sales estimate of $92.91 million provided in the context. The company guided for non-GAAP diluted EPS between $2.06 and $2.21, with the midpoint ($2.135) also trending above the analyst EPS estimate of $2.16.
- Q1 2026 Outlook: For the first quarter, the company anticipates revenue of $21.0 million to $22.0 million and non-GAAP EPS of $0.44 to $0.48. The revenue midpoint is slightly above the analyst estimate of $21.21 million, while the EPS midpoint aligns closely with the estimate of $0.47.
Key Highlights from the Earnings Release
Beyond the headline numbers, the press release emphasized several strategic and operational milestones:
- Dividend Increase: The board of directors declared a 17.6% increase in the regular quarterly cash dividend, raising it to $0.20 per share from $0.17. This is payable on March 6, 2026, to shareholders of record as of February 23, 2026.
- Product Launch Milestone: The company successfully shipped the initial units of its next-generation 3870 MRI-compatible IV infusion pump in Q4 2025. Management stated that a full rollout is expected to begin in Q1 2026, with "real acceleration and meaningful revenue contribution" anticipated in the second half of the year.
- Strong Profitability: The company maintained a robust gross profit margin of approximately 77% for the full year. It also reported strong free cash flow of $16.5 million for 2025, even after significant capital expenditures related to the completion of its new corporate office.
Conclusion
IRadimed concluded a strong 2025 by beating quarterly estimates and raising its dividend, a combination that typically resonates well with investors. The positive pre-market movement suggests the market is rewarding the earnings beat and the confident outlook for 2026, which is anchored by the upcoming launch of its new 3870 infusion pump system. The company’s guidance implies a continuation of its growth trajectory, positioning it to potentially exceed current analyst expectations for the full year.
For a detailed breakdown of historical earnings and future analyst estimates for IRadimed, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investing involves risk, including the potential loss of principal.
